Editor Jean L. Wright

2019

As a physician, I have always been interested in how to balance the risk of toxicity related to our treatment recommendations versus the potential benefits. In breast cancer, in particular, I found that this risk-benefit assessment plays into almost every treatment decision and that “gray zone” cases, where there is no clear-cut management pathway, make up the majority of the cases I see.